What is Supernus Pharmaceuticals's D&A?

Supernus Pharmaceuticals (SUPN) reported D&A of $26.13M in Q1 2026.

How has Supernus Pharmaceuticals's D&A changed year-over-year?

Supernus Pharmaceuticals's D&A increased by 28.2% year-over-year, from $20.38M to $26.13M.

What is the long-term trend for Supernus Pharmaceuticals's D&A?

Over 4 years (2021 to 2025), Supernus Pharmaceuticals's D&A has grown at a 29.5% compound annual growth rate (CAGR), from $32.6M to $91.56M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Supernus Pharmaceuticals SUPN D&A

D&A at other companies

Rapport Therapeutics, Inc.RAPP

$227K-7.0%

Axsome TherapeuticsAXSM

$116K-22.1%

Neurocrine BiosciencesNBIX

$7.2M+9.1%

Jazz PharmaceuticalsJAZZ

$9.1M-12.5%

Acadia PharmaceuticalsACAD

$271K+18.3%

Catalyst PharmaceuticalCPRX

$70K-39.1%

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.58B+62.8%

Enterprise value$2.44B+62.3%

P/S3.3×+0.9×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's D&A?: Supernus Pharmaceuticals (SUPN) reported D&A of $26.13M in Q1 2026.
How has Supernus Pharmaceuticals's D&A changed year-over-year?: Supernus Pharmaceuticals's D&A increased by 28.2% year-over-year, from $20.38M to $26.13M.
What is the long-term trend for Supernus Pharmaceuticals's D&A?: Over 4 years (2021 to 2025), Supernus Pharmaceuticals's D&A has grown at a 29.5% compound annual growth rate (CAGR), from $32.6M to $91.56M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.